Tumor Biology

, Volume 35, Issue 1, pp 469–473 | Cite as

Prognostic role of cytovillin expression in patients with osteosarcoma: a meta-analysis

  • Shibing Guo
  • Rui Bai
  • Wei Zhao
  • Yuxin Wang
  • Zhenqun Zhao
  • Wei Feng
Research Article
First Online:
Received:
Accepted:

Abstract

Cytovillin plays structural and regulatory roles in the assembly and stabilization of specialized plasma membrane domains and in the tumor angiogenesis. Cytovillin expression has been proposed to be an effective biomarker of prognosis in patients with osteosarcoma, and many studies have been performed to assess the prognostic role of cytovillin expression in patients with osteosarcoma. We performed this meta-analysis to provide a comprehensive evaluation of the role of cytovillin expression on the overall survival rate by calculating the pooled risk ratio (RR) with corresponding 95 % confidence interval (95 % CI). Finally, eight studies with a total of 415 patients with osteosarcoma were included into the meta-analysis. Meta-analysis of total eight studies showed that cytovillin expression was obviously associated with lower overall survival rate in patients with osteosarcoma (RR = 0.41, 95 % CI 0.28–0.58, P < 0.001). Meta-analysis of five studies with large sample still showed that cytovillin expression was obviously associated with lower overall survival rate (RR = 0.48, 95 % CI 0.38–0.60, P < 0.001). In conclusion, the meta-analysis shows that cytovillin expression is obviously associated with lower overall survival rate in patients with osteosarcoma, and it is an effective biomarker of prognosis.

Keywords

Osteosarcoma Cytovillin Prognosis Meta-analysis 
This is a preview of subscription content, log in to check access.

Notes

Conflicts of interest

None

References

  1. 1.
    Ritter J, Bielack SS. Osteosarcoma. Ann Oncol. 2010;21 Suppl 7:vii320–325.PubMedGoogle Scholar
  2. 2.
    Osborne TS, Khanna C. A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol. 2012;146:132–42.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Masrouha KZ, Khattab R, Tawil A, Abdallah A, Saghieh S, Haidar R, et al. A preliminary investigation of beta-hCG expression in patients with osteosarcoma. J Bone Joint Surg Br. 2012;94:419–24.PubMedCrossRefGoogle Scholar
  4. 4.
    Poletajew S, Fus L, Wasiutynski A. Current concepts on pathogenesis and biology of metastatic osteosarcoma tumors. Ortop Traumatol Rehabil. 2011;13:537–45.PubMedCrossRefGoogle Scholar
  5. 5.
    Turunen O, Winqvist R, Pakkanen R, Grzeschik KH, Wahlstrom T, Vaheri A. Cytovillin, a microvillar Mr 75,000 protein. cDNA sequence, prokaryotic expression, and chromosomal localization. J Biol Chem. 1989;264:16727–32.PubMedGoogle Scholar
  6. 6.
    Pakkanen R. Immunofluorescent and immunochemical evidence for the expression of cytovillin in the microvilli of a wide range of cultured human cells. J Cell Biochem. 1988;38:65–75.PubMedCrossRefGoogle Scholar
  7. 7.
    Bretscher A, Reczek D, Berryman M. Ezrin: a protein requiring conformational activation to link microfilaments to the plasma membrane in the assembly of cell surface structures. J Cell Sci. 1997;110(Pt 24):3011–8.PubMedGoogle Scholar
  8. 8.
    Kim MS, Song WS, Cho WH, Lee SY, Jeon DG. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res. 2007;459:229–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Salas S, Bartoli C, Deville JL, Gaudart J, Fina F, Calisti A, et al. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch. 2007;451:999–1007.PubMedCrossRefGoogle Scholar
  10. 10.
    Shen XD, Lin F, Chen P, Zhao H. Expression of ezrin protein and its relationship with lung metastasis and survival time of osteosarcoma patients. Tumor. 2008;28:260–7.Google Scholar
  11. 11.
    Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, et al. Clinical value of ezrin expression in primary osteosarcoma. Cancer Res Treat. 2009;41:138–44.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Xu-Dong S, Zan S, Shui-er Z, Li-na T, Wen-xi Y, Feng L, et al. Expression of ezrin correlates with lung metastasis in Chinese patients with osteosarcoma. Clin Invest Med. 2009;32:E180–188.PubMedGoogle Scholar
  13. 13.
    Boldrini E, Peres SV, Morini S, de Camargo B. Immunoexpression of ezrin and CD44 in patients with osteosarcoma. J Pediatr Hematol Oncol. 2010;32:e213–217.PubMedCrossRefGoogle Scholar
  14. 14.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  15. 15.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRefGoogle Scholar
  16. 16.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  17. 17.
    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRefGoogle Scholar
  18. 18.
    Di Cristofano C, Leopizzi M, Miraglia A, Sardella B, Moretti V, Ferrara A, et al. Phosphorylated ezrin is located in the nucleus of the osteosarcoma cell. Mod Pathol. 2010;23:1012–20.PubMedCrossRefGoogle Scholar
  19. 19.
    Min DL, Shen Z, Lin F, Xu X, Huang W. Clinical significances of Runx2 and ezrin expressions in osteosarcoma. China Oncology. 2012;22:685–9.Google Scholar
  20. 20.
    McHugh JB, Thomas DG, Herman JM, Ray ME, Baker LH, Adsay NV, et al. Primary versus radiation-associated craniofacial osteosarcoma: biologic and clinicopathologic comparisons. Cancer. 2006;107:554–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Park HR, Cabrini RL, Araujo ES, Paparella ML, Brandizzi D, Park YK. Expression of ezrin and metastatic tumor antigen in osteosarcomas of the jaw. Tumori. 2009;95:81–6.PubMedGoogle Scholar
  22. 22.
    Machado I, Navarro S, Giner F, Alberghini M, Bertoni F, Llombart-Bosch A. Ezrin immunohistochemical expression in chondrosarcomas, osteosarcomas and Ewing sarcoma family of tumors. Virchows Arch. 2010;457:87–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Wang YF, Shen JN, Xie XB, Wang J, Huang G. Expression change of ezrin as a prognostic factor in primary osteosarcoma. Med Oncol. 2011;28 Suppl 1:S636–643.PubMedCrossRefGoogle Scholar
  24. 24.
    Brambilla D, Fais S. The Janus-faced role of ezrin in “linking” cells to either normal or metastatic phenotype. Int J Cancer. 2009;125:2239–45.PubMedCrossRefGoogle Scholar
  25. 25.
    Neisch AL, Fehon RG. Ezrin, radixin and moesin: key regulators of membrane-cortex interactions and signaling. Curr Opin Cell Biol. 2011;23:377–82.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Shibing Guo
    • 1
  • Rui Bai
    • 1
  • Wei Zhao
    • 1
  • Yuxin Wang
    • 1
  • Zhenqun Zhao
    • 1
  • Wei Feng
    • 1
  1. 1.Department of Bone OncologyThe Second Affiliated Hospital of Inner Mongolia Medical UniversityHohhotChina

Personalised recommendations